An experimental obesity drug may be causing higher incidences of depression, insomnia and suicidal anxiety according to several media reports. Acomplia, made by Sanofi-Aventis, has been shown to help lower weight, cholesterol and blood sugar.

A ruling about FDA approval is expected on July 27. The FDA briefing is available online.